- Home
- FLYX vs MRSN Comparison
FLYX vs MRSN Comparison
Compare FLYX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- MRSN
- Stock Information
- Founded
- FLYX 2015
- MRSN 2001
- Country
- FLYX United States
- MRSN United States
- Employees
- FLYX N/A
- MRSN N/A
- Industry
- FLYX Blank Checks
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FLYX Finance
- MRSN Health Care
- Exchange
- FLYX Nasdaq
- MRSN Nasdaq
- Market Cap
- FLYX 39.4M
- MRSN 34.0M
- IPO Year
- FLYX N/A
- MRSN 2017
- Fundamental
- Price
- FLYX $2.39
- MRSN $6.85
- Analyst Decision
- FLYX
- MRSN Strong Buy
- Analyst Count
- FLYX 0
- MRSN 5
- Target Price
- FLYX N/A
- MRSN $5.75
- AVG Volume (30 Days)
- FLYX 13.5K
- MRSN 132.7K
- Earning Date
- FLYX 08-13-2025
- MRSN 08-12-2025
- Dividend Yield
- FLYX N/A
- MRSN N/A
- EPS Growth
- FLYX N/A
- MRSN N/A
- EPS
- FLYX N/A
- MRSN N/A
- Revenue
- FLYX $335,427,000.00
- MRSN $34,006,000.00
- Revenue This Year
- FLYX $28.47
- MRSN N/A
- Revenue Next Year
- FLYX $22.44
- MRSN $1.03
- P/E Ratio
- FLYX N/A
- MRSN N/A
- Revenue Growth
- FLYX 5.38
- MRSN N/A
- 52 Week Low
- FLYX $1.79
- MRSN $6.47
- 52 Week High
- FLYX $4.90
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- FLYX 47.90
- MRSN 39.66
- Support Level
- FLYX $2.01
- MRSN $6.55
- Resistance Level
- FLYX $2.59
- MRSN $10.25
- Average True Range (ATR)
- FLYX 0.24
- MRSN 0.65
- MACD
- FLYX 0.00
- MRSN -0.21
- Stochastic Oscillator
- FLYX 55.16
- MRSN 8.11
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.